Agreement - January 13, 2014
Santaris Pharma announce agreement with GSK to develop RNA-targeted medicines
Santaris Pharma A/S have announced that they have signed an agreement with GlaxoSmithKline (GSK), whereby, pursuant to an option right, GSK gains access to Santaris’ Locked Nucleic Acid (LNA) technology to develop RNA-targeted medicines. Under the terms of the agreement, GSK can obtain rights to utilize Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform […]
Agreement - January 10, 2014
Nuevolution Announces Technology Licensing Agreement
Nuevolution has announced that it has entered into a non-exclusive technology licensing agreement with Novartis for use of Nuevolution’s Chemetics technology. The Chemetics platform uses proprietary innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale forming drug-like small molecules for lead discovery. The technology allows efficient screening of billions of molecules against […]
Agreement - January 8, 2014
Applied BioCode signs license and supply agreement with genetic analysis for BMB technology
Applied BioCode announced today that it has signed a License and Supply Agreement for its Barcoded Magnetic Bead (BMB) technology with Genetic Analysis of Oslo, Norway. The license from Applied BioCode will give Genetic Analysis access to specific Applied BioCode BMB patents and BioCode analyzers for Molecular Diagnostic testing of microbial imbalances in the GI […]
Agreement - January 7, 2014
Shire extends expiration of tender offer for all outstanding shares of ViroPharma
Shire announces that it has extended the expiration of its previously announced tender offer by a wholly owned subsidiary of Shire for all of the outstanding common shares of ViroPharma until midnight, New York City time, on Thursday, January 9, 2014 (one minute after 11:59 p.m., New York City time, on January 9, 2014). The […]
Agreement - December 20, 2013
AstraZeneca buys Bristol-Myers Squibb share of global diabetes alliance assets
According to the agreement AstraZeneca will acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance for an initial consideration of $2.7 billion on completion and up to $1.4 billion in regulatory, launch and sales-related payments. Furthermore, AstraZeneca has agreed to pay various sales-related royalty payments up until 2025. In addition, AstraZeneca states […]
Agreement - December 16, 2013
New agreement on collaboration rules
Public healthcare and the pharma, medtech and laboratory technical industries get new collaboration rules. Swedish Medtech has entered an agreement with the Swedish Association of Local Authorities and Regions, the trade association for the research-based pharmaceutical industry (LIF) and Swedish Labtech about the collaboration rules. The new agreement describes the parties view on product and […]
